Tislelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy for ESCC
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Tislelizumab Inhibitor Plus Neoadjuvant Chemotherapy Versus Plus Neoadjuvant
Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a
Multicenter, Randomized, Controlled Phase III Clinical Study